There are currently 43 active clinical trials seeking participants for Neuroblastoma research studies. The states with the highest number of trials for Autism participants are California, Texas, New York and Florida.
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
All
Ages:
22 years and below
Trial Updated:
04/04/2024
Locations: University of Alabama, Children's of Alabama, Birmingham, Alabama +25 locations
Conditions: Neuroblastoma
Register for Updates
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
NCT03541720
Recruiting
PET (positron emission tomography) scans combined with a radioactive tracer will be used to identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to see the very small areas of the disease. 18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma. With this... Read More
Gender:
All
Ages:
1 year and above
Trial Updated:
03/29/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma, Pheochromocytoma
Register for Updates
A Study of N9 Chemotherapy in Children With Neuroblastoma
NCT04947501
Recruiting
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV).
Gender:
All
Ages:
Between 1 year and 19 years
Trial Updated:
03/13/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Pediatric Cancer
Register for Updates
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
NCT00107289
Recruiting
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Gender:
All
Ages:
1 year and above
Trial Updated:
03/08/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Pheochromocytoma
Register for Updates
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
NCT05135975
Recruiting
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly... Read More
Gender:
All
Ages:
Between 18 months and 40 years
Trial Updated:
02/26/2024
Locations: Children's Hospital of Alabama/UAB, Birmingham, Alabama +3 locations
Conditions: Neuroblastoma, Sarcoma
Register for Updates
International PPB/DICER1 Registry
NCT03382158
Recruiting
Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which wil... Read More
Gender:
All
Ages:
All
Trial Updated:
02/07/2024
Locations: Children's Minnesota, Minneapolis, Minnesota
Conditions: Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Register for Updates
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755
Recruiting
This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
Gender:
All
Ages:
21 years and below
Trial Updated:
01/29/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +68 locations
Conditions: Acute Lymphoblastic Leukemia, Rhabdomyosarcoma, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Soft Tissue Sarcoma
Register for Updates
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
NCT06057948
Recruiting
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Gender:
All
Ages:
All
Trial Updated:
01/22/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey +6 locations
Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
All
Ages:
All
Trial Updated:
12/17/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona +7 locations
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
MCT for the Harvard/UCSF ROBIN Center
NCT06000787
Recruiting
The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the de... Read More
Gender:
All
Ages:
All
Trial Updated:
12/06/2023
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Glioma, Childhood Brainstem, Neuroblastoma
Register for Updates
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
NCT04040088
Recruiting
This trial studies how well an investigational scan called 68Ga-DOTATATE PET/CT works in diagnosing pediatric patients with neuroendocrine tumors that have spread to other places in the body (metastatic). A neuroendocrine tumor is an abnormal growth of neuroendocrine cells, which are cells resembling nerve cells and hormone-producing cells. 68Ga-DOTATATE is a radioactive substance called a radiotracer that when used with PET/CT scans, may work better than standard of care MIBG scans in diagnosin... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
12/01/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Ganglioneuroblastoma, Ganglioneuroma, Neuroblastoma
Register for Updates
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma
NCT05400603
Recruiting
High risk neuroblastoma is an aggressive and often lethal pediatric solid tumor. Survival remains less than 50% and those patients who do survive suffer many treatment-related acute and chronic toxicities. Chemoimmunotherapy using a combination of an anti-GD2 monoclonal antibody (dinutuximab) and different chemotherapy agents in the relapsed/refractory (r/r) neuroblastoma population, has demonstrated the most robust response rates to date, shifting the clinical practice to administer chemoimmuno... Read More
Gender:
All
Ages:
Between 12 months and 16 years
Trial Updated:
11/21/2023
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma
Register for Updates